Oral News and Research

RSS

Scientists create artificial skin from stem cells of umbilical cord

Spanish scientists, from the Tissue Engineering Research Group, from the Dept. of Histology at the University of Granada, have managed, for the first time, to grow artificial skin from stem cells of umbilical cord.

25 Nov 2013

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

A UC San Francisco investigator has won an eight-year grant from the National Cancer Institute for a major investigation into anal cancer, a debilitating and sometimes fatal disease largely concentrated among people with HIV.

25 Nov 2013

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

Janssen-Cilag International NV announced today that the European Commission has approved INVOKANA (canagliflozin) in the European Union for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control[1]. Canagliflozin is an oral, once-daily medication, which belongs to a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors.

23 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Incidence of oropharyngeal cancer on the rise

NCI scientists report that the incidence of oropharyngeal cancer significantly increased during the period 1983-2002 among people in countries that are economically developed.

22 Nov 2013

Sugar is not direct cause of tooth decay

The effects of sugar on teeth are widely talked about. How many times have you been told that if you eat sugar, you will damage your teeth and develop cavities?

22 Nov 2013

Multiple sclerosis researchers receive NMSS drug development grant

A $500,000 drug development grant from the National Multiple Sclerosis Society was awarded to a partnership between a multiple sclerosis research team at the Icahn School of Medicine at Mount Sinai and Karyopharm Therapeutics Inc., a clinical stage pharmaceutical company. Dr. Patrizia Casaccia, MD, PhD, Professor in the Departments of Neuroscience and Genetics and Genomics, at Icahn School of Medicine at Mount Sinai, will be the academic lead.

21 Nov 2013

Adverse events linked with HPV vaccine appear to be related with media coverage

The number of adverse events associated with the HPV vaccine reported to the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) appeared to be related to media coverage and online controversy about the vaccine, finds a study in the Journal of Adolescent Health.

20 Nov 2013

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

20 Nov 2013

Researchers report long-term benefits of gene therapy in advanced heart failure patients

Researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai reported the long-term benefits of a single dose of their gene therapy AAV1/SERCA2a in advanced heart failure patients on Nov. 19 at the American Heart Association Scientific Sessions 2013.

20 Nov 2013

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Stroke is the leading cause of serious long-term disability and death in the US. In addition to lifestyle changes, medications such as anti-blood clotting drugs are helpful in the prevention of stroke.

20 Nov 2013

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic dermatitis (eczema).

19 Nov 2013

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

Research presented today, at the 117th Annual Meeting of the American Academy of Ophthalmology in New Orleans, has found that women who have taken oral contraceptives for three or more years are twice as likely to suffer from glaucoma, one of the leading causes of blindness which affects nearly 60 million worldwide. The researchers caution gynecologists and ophthalmologists to be aware of the fact that oral contraceptives might play a role in glaucomatous diseases, and inform patients to have their eyes screened for glaucoma if they also have other risk factors.

19 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Cardiovascular Institute researchers to showcase 22 abstracts at upcoming AHA Scientific Sessions

Researchers from the Cardiovascular Institute at Rhode Island, The Miriam and Newport hospitals will present 22 abstracts, both poster and oral presentations, at the upcoming American Heart Association Scientific Sessions, to be held in Dallas November 16-20, 2013. Scientific Sessions is the foremost cardiovascular research meeting in the U.S., with more than 18,000 cardiovascular experts from more than 105 countries in attendance.

16 Nov 2013

Concordia University professors use funds to fight fungus and update aircraft

Thanks to new funding from the Government of Canada, two Concordia University professors just might create a greener aerospace industry and help cure fungal infections.

16 Nov 2013

Diplomat selected as provider of IMBRUVICA capsules for MCL treatment

Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration for the treatment of Mantle Cell Lymphoma.

16 Nov 2013

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that its wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd., has entered into a supply arrangement with Pharmacyclics, Inc.

15 Nov 2013

Scientists discover new drug mechanism to reduce risk of infections

Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered the exact mode of action by plerixafor, a drug commonly prescribed to stimulate immune responses in patients suffering from neutropenia, which causes them to become prone to oral, skin, genital infections and in worst cases, a fatal whole-body infection.

15 Nov 2013

Over 50% of nonsurgical patients prescribed opioids during hospitalizations, analysis finds

Amid a growing climate of concern regarding the overuse of opioid pain medications, a comprehensive analysis of more than 1 million hospital admissions has found that over 50 percent of all nonsurgical patients were prescribed opioids during their hospitalizations -- often at very high doses -- and that more than half of those exposed were still receiving these medications on the day they were discharged from the hospital.

14 Nov 2013

Oral News and Research

Scientists create artificial skin from stem cells of umbilical cord

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

EC approves INVOKANA (canagliflozin) medication for adults with type 2 diabetes mellitus

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Incidence of oropharyngeal cancer on the rise

Sugar is not direct cause of tooth decay

Multiple sclerosis researchers receive NMSS drug development grant

Adverse events linked with HPV vaccine appear to be related with media coverage

Tasquinimod drug effective for men with metastatic castration-resistant prostate cancer

Researchers report long-term benefits of gene therapy in advanced heart failure patients

Once-daily edoxaban prevents stroke in patients with atrial fibrillation

Atopix recruits first patient in OC459 Phase 2 trial for treatment of atopic dermatitis

Research shows oral contraceptive use over three years could be a risk factor for glaucoma

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Cardiovascular Institute researchers to showcase 22 abstracts at upcoming AHA Scientific Sessions

Concordia University professors use funds to fight fungus and update aircraft

Diplomat selected as provider of IMBRUVICA capsules for MCL treatment

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

Scientists discover new drug mechanism to reduce risk of infections

Over 50% of nonsurgical patients prescribed opioids during hospitalizations, analysis finds

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News